An efficient, versatile linker is developed for the synthesis of C-terminal primary/secondary amides and hydrazides as well as peptide alcohols, which is compatible with solid-phase peptide synthesis (SPPS) and suppresses side reactions. It is termed as Ramage Linker.
The basis for the Ramage linker is a dibenzocyclohepta-1,3-dienyl system with an additional oxygen substituent which serves on one hand for further stabilization. The Ramage linker represents an alternative to the commonly used Rinklinker for the synthesis of C-terminal peptide amides. The three-circular structure of the Ramage linker prevents its fragmentation cleavage from the resin followed by back alkylation. This is a drawback commonly observed during peptide synthesis with the Rinklinker. Consequently, the Ramage linker delivers peptides in higher purity with less impurities compared to peptides produced with the Rinklinker.
Besides C-terminal amides, the Ramage linker can also be used for the synthesis of C-terminal peptide alcohols.
Their diverse biological activities and clinical importance are described in various publications. One prominent example is Octreotide, a metabolically stable analog of somatostatin which contains threoninol at the C-terminus. Starting from the Ramage linker or resin, the deprotected primary amine can be converted to a hydroxy moiety and further to the corresponding chloride, which can then be loaded with Fmoc-amino alcohols. Analogous to the preparation of peptide amides, the synthesized sequence can be detached from the linker and fully deprotected by conventional reagents.
References:
- Design of a versatile linker for solid phase peptide synthesis: Synthesis of C-terminal primary / secondary amides and hydrazides; R. Ramage, S. L. Irving and C. McInnes; Tetrahedron Lett 1993; 34: 6599-6602
- Functionalized Resins for the Synthesis of Peptide Alcohols; F. J. Ferrer Gago, L. Q. Koh, D. P. Lane; Chem. Eur. J. 2020; 26(2): 379-383
A newly developed drug stabilizes dopamine and serotonin levels using a novel mechanism. It effectively treats psychosis in patients with schizophrenia, and researchers are testing its efficacy for Parkinson’s disease as well.
The threat of antibiotic resistance rises as bacteria continue to evolve to foil even the most powerful modern drug treatments. By 2050, antibiotic resistant-bacteria threaten to claim more than 10 million lives as existing therapies prove ineffective.
According to the World Health Organization, about 785 million people around the world lack a clean source of drinking water. Despite the vast amount of water on Earth, most of it is seawater and freshwater accounts for only about 2.5% of the total. One of the ways to provide clean drinking water is to desalinate seawater. The Korea Institute of Civil Engineering and Building Technology (KICT) has announced the development of a stable performance electrospun nanofiber membrane to turn seawater into drinking water by membrane distillation process.
Clariant, a focused, sustainable and innovative speciality chemical company, has reached definitive agreements for the divestment of its Pigments business to a consortium of Heubach Group (“Heubach”) and SK Capital Partners (“SK Capital”)
The latest survey of British Coatings Federation (BCF) members reveals UK coatings manufacturers are increasingly concerned about the effects of the new UK chemical regulations.
Shipping costs have risen sharply and fierce competition for ocean freight capacity is the new normal. With new capacity only slowly coming onstream, freight rates are expected to continue to reach new highs this year and will remain above their pre-pandemic levels in the longer term.
AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Ammonia saved the world once; it might do it again. A century ago, the world faced a looming food crisis. A booming population was pushing farmers to grow crops faster than nitrogen-fixing bacteria in the soil could keep up, and the South American deposits of guano and natural nitrates they applied as fertilizer were dwindling.
Lipids are an unsung component in the two mRNA-based shots, the only vaccines to be approved so far in the US. Naked mRNA quickly degrades in the body and can trigger an unwanted immune reaction. To get the genetic material to its target cells, vaccine developers combine it with a mixture of several sophisticated lipids to form lipid nanoparticles, or LNPs. mRNA vaccine producers use a package of 4 lipids to formulate their LNPs